ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $3.51M invested in ProShares UltraShort NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
2
Reduced
2
Closed
3
Calls
$560K
Puts
$211K
Net Calls
+$349K
Net Calls Change
+$257K
Top Buyers
1 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$1.44M |
2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$332K |
3 |
VF
Virtu Financial
New York
|
+$319K |
4 |
HF
HRT Financial
New York
|
+$228K |
5 |
Morgan Stanley
New York
|
+$5.81K |
Top Sellers
1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$3.45M |
2 |
Jane Street
New York
|
-$979K |
3 |
GCM
Gunderson Capital Management
Mt. Pleasant,
South Carolina
|
-$918K |
4 |
Citadel Advisors
Miami,
Florida
|
-$68.8K |
5 |
UBS Group
Zurich,
Switzerland
|
-$18.7K |